PARPi olaparib and talazoparib are only approved for treatment of metastatic BC patients based on gBRCA1/2m and no clinical evidence has been generated indicating a benefit for selected therapies based on somatic mutation status of BRCA1/2. The gene discussed is BRCA1; the disease is breast cancer.